Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136648532> ?p ?o ?g. }
- W3136648532 endingPage "556" @default.
- W3136648532 startingPage "544" @default.
- W3136648532 abstract "Bruton tyrosine kinase (BTK) inhibitors are highly active drugs for the treatment of chronic lymphocytic leukemia (CLL). To understand the response to BTK inhibitors on a molecular level, we performed (phospho)proteomic analyses under ibrutinib treatment. We identified 3466 proteins and 9184 phosphopeptides (representing 2854 proteins) in CLL cells exhibiting a physiological ratio of phosphorylated serines (pS), threonines (pT), and tyrosines (pY) (pS:pT:pY). Expression of 83 proteins differed between unmutated immunoglobulin heavy-chain variable region (IGHV) CLL (UM-CLL) and mutated IGHV CLL (M-CLL). Strikingly, UM-CLL cells showed higher basal phosphorylation levels than M-CLL samples. Effects of ibrutinib on protein phosphorylation levels were stronger in UM-CLL, especially on phosphorylated tyrosines. The differentially regulated phosphopeptides and proteins clustered in pathways regulating cell migration, motility, cytoskeleton composition, and survival. One protein, myristoylated alanine-rich C-kinase substrate (MARCKS), showed striking differences in expression and phosphorylation level in UM-CLL vs M-CLL. MARCKS sequesters phosphatidylinositol-4,5-bisphosphate, thereby affecting central signaling pathways and clustering of the B-cell receptor (BCR). Genetically induced loss of MARCKS significantly increased AKT signaling and migratory capacity. CD40L stimulation increased expression of MARCKS. BCR stimulation induced phosphorylation of MARCKS, which was reduced by BTK inhibitors. In line with our in vitro findings, low MARCKS expression is associated with significantly higher treatment-induced leukocytosis and more pronounced decrease of nodal disease in patients with CLL treated with acalabrutinib." @default.
- W3136648532 created "2021-03-29" @default.
- W3136648532 creator A5001242672 @default.
- W3136648532 creator A5019866348 @default.
- W3136648532 creator A5021332351 @default.
- W3136648532 creator A5023752156 @default.
- W3136648532 creator A5024254750 @default.
- W3136648532 creator A5025985392 @default.
- W3136648532 creator A5030524385 @default.
- W3136648532 creator A5035734503 @default.
- W3136648532 creator A5035800074 @default.
- W3136648532 creator A5041621560 @default.
- W3136648532 creator A5042259957 @default.
- W3136648532 creator A5042919966 @default.
- W3136648532 creator A5043791269 @default.
- W3136648532 creator A5048054782 @default.
- W3136648532 creator A5052133938 @default.
- W3136648532 creator A5058590537 @default.
- W3136648532 creator A5061682665 @default.
- W3136648532 creator A5067592137 @default.
- W3136648532 creator A5067845923 @default.
- W3136648532 creator A5070519285 @default.
- W3136648532 creator A5073077636 @default.
- W3136648532 creator A5076077834 @default.
- W3136648532 creator A5081032431 @default.
- W3136648532 creator A5082142875 @default.
- W3136648532 creator A5082709827 @default.
- W3136648532 creator A5086557136 @default.
- W3136648532 creator A5088826331 @default.
- W3136648532 date "2021-03-18" @default.
- W3136648532 modified "2023-10-18" @default.
- W3136648532 title "MARCKS affects cell motility and response to BTK inhibitors in CLL" @default.
- W3136648532 cites W1429374962 @default.
- W3136648532 cites W1589053023 @default.
- W3136648532 cites W1594865953 @default.
- W3136648532 cites W1967973357 @default.
- W3136648532 cites W1969953749 @default.
- W3136648532 cites W1970584505 @default.
- W3136648532 cites W1971163722 @default.
- W3136648532 cites W1975706139 @default.
- W3136648532 cites W1980881522 @default.
- W3136648532 cites W1984046622 @default.
- W3136648532 cites W1986375719 @default.
- W3136648532 cites W1986924929 @default.
- W3136648532 cites W1990986028 @default.
- W3136648532 cites W1994036293 @default.
- W3136648532 cites W1996992222 @default.
- W3136648532 cites W1997958695 @default.
- W3136648532 cites W2002243207 @default.
- W3136648532 cites W2004739040 @default.
- W3136648532 cites W2006900120 @default.
- W3136648532 cites W2006909007 @default.
- W3136648532 cites W2008336038 @default.
- W3136648532 cites W2008965900 @default.
- W3136648532 cites W2009179957 @default.
- W3136648532 cites W2011950935 @default.
- W3136648532 cites W2025057435 @default.
- W3136648532 cites W2031232800 @default.
- W3136648532 cites W2033442675 @default.
- W3136648532 cites W2035916624 @default.
- W3136648532 cites W2037199116 @default.
- W3136648532 cites W2037953589 @default.
- W3136648532 cites W2051321376 @default.
- W3136648532 cites W2057312796 @default.
- W3136648532 cites W2081098333 @default.
- W3136648532 cites W2086637735 @default.
- W3136648532 cites W2087835012 @default.
- W3136648532 cites W2101163066 @default.
- W3136648532 cites W2107665951 @default.
- W3136648532 cites W2110799171 @default.
- W3136648532 cites W2111609050 @default.
- W3136648532 cites W2112873967 @default.
- W3136648532 cites W2113472355 @default.
- W3136648532 cites W2114566045 @default.
- W3136648532 cites W2114570899 @default.
- W3136648532 cites W2114675572 @default.
- W3136648532 cites W2124439357 @default.
- W3136648532 cites W2133732014 @default.
- W3136648532 cites W2142160913 @default.
- W3136648532 cites W2144513020 @default.
- W3136648532 cites W2156867352 @default.
- W3136648532 cites W2165923048 @default.
- W3136648532 cites W2206193651 @default.
- W3136648532 cites W2211564719 @default.
- W3136648532 cites W2265529387 @default.
- W3136648532 cites W2276931949 @default.
- W3136648532 cites W2297519944 @default.
- W3136648532 cites W2343292502 @default.
- W3136648532 cites W2523379938 @default.
- W3136648532 cites W2561088362 @default.
- W3136648532 cites W2561449166 @default.
- W3136648532 cites W2607497479 @default.
- W3136648532 cites W2622857768 @default.
- W3136648532 cites W2731837829 @default.
- W3136648532 cites W2744781811 @default.
- W3136648532 cites W2753995352 @default.
- W3136648532 cites W2782258326 @default.
- W3136648532 cites W2785372204 @default.